<DOC>
	<DOCNO>NCT02244112</DOCNO>
	<brief_summary>The purpose Phase 1 study evaluate effect food pharmacokinetics ( PK ) oprozomib , drug-drug interaction oprozomib midazolam , safety tolerability oprozomib patient advanced malignancy</brief_summary>
	<brief_title>A Phase 1 Study Oprozomib Assess Food Effect , Drug-Drug Interaction With Midazolam , Safety Tolerability Patients With Advanced Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>Key 1 . Histologically confirm diagnosis advanced malignancy . 2 . Relapsed standard therapy malignancy , standard therapy define , relapse investigational therapy consider treat physician appropriate candidate Phase 1 clinical study 3 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 02 4 . Adequate hepatic function , bilirubin ≤ 1.5 time upper limit normal ( ULN ) absence Gilbert 's disease hemolysis , alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤ 3 time ULN . 5 . Absolute neutrophil count ( ANC ) ≥ 1000/mm3 . Screening ANC must independent myeloid growth factor support least 1 week , pegylated growth factor 2 week . 6 . Hemoglobin &gt; 7g/dL . Patients may receive red blood cell ( RBC ) transfusion erythropoietin darbepoetin accordance institutional guideline 1 week screening . 7 . Platelet count &gt; 30,000 mm3 . Patients receive platelet transfusion least 1 week screening . 8 . Uric acid , elevate , must lower less ULN . 9 . Calculated measured creatinine clearance ( CrCl ) ≥ 30 mL/min calculate use formula Cockcroft Gault [ ( 140 age ) × mass ( kg ) / ( 72 × serum creatinine mg/dL ) ] . Multiply result 0.85 female . Key 1 . Recovered ( i.e. , ≤ Grade 1 toxicity patient 's baseline status ) reversible nonhematologic effect prior anticancer therapy , exclude alopecia . 2 . Systemic chemotherapy approve investigational anticancer therapeutic , include steroid therapy intend treat underlie malignancy , within 3 week first oprozomib dose ; antibody therapy , minimum 3 halflives must elapse first oprozomib dose . 3 . Radiation therapy within 3 week first oprozomib dose . Radioimmunotherapy within 8 week first oprozomib dose . 4 . Autologous stem cell transplant ( ASCT ) within 8 week allogeneic SCT within 16 week prior initiation study treatment . Patients prior allogeneic SCT must evidence moderatetosevere graftversushost disease ( define Filipovich 2005 ) . 5 . Unresolved toxicity ( NCICTCAE version 4.03 ) ≥ Grade 2 previous anticancer therapy , except alopecia . 6 . Major surgery within 3 week first oprozomib dose . 7 . Congestive heart failure ( New York Heart Association Class III IV ) 8 . Symptomatic cardiac ischemia . 9 . Conduction abnormality uncontrolled conventional intervention , include limited persistent permanent atrial fibrillation . 10 . History ventricular fibrillation ventricular tachycardia . 11 . History torsade de pointe . 12 . Myocardial infarction within 6 month first dose . 13 . Abnormal measurement 12lead ECG . 14 . Uncontrolled diabetes mellitus hypertension 15 . Dysphagia inability swallow tablet . 16 . Insufficiency exocrine pancreas , steatorrhea , disorder digestive system impair absorption . 17 . Resection portion stomach intestine , exception appendectomy . 18 . History bariatric surgery , except case bowel resect device remove . 19 . Active infection require systemic antibiotic , antiviral , antifungal within 2 week first dose , unless culture polymerase chain reaction ( PCR ) negative 14 day . 20 . Known human immunodeficiency virus ( HIV ) positive , hepatitis B surface antigenpositive , suspect hepatitis C infection . 21 . Primary malignancy central nervous system . 22 . Patient symptomatic brain metastasis . Patients brain metastasis must stable neurologic status follow surgery radiation least 2 week completion definitive therapy , AND without neurologic dysfunction would confound evaluation neurologic adverse event . 23 . Significant peripheral neuropathy ( Grade 2 pain ≥ Grade 3 ) . 24 . Systemic treatment strong inhibitor Pglycoprotein ( [ Pgp ] ; i.e. , itraconazole , ketoconazole ) within 14 day first dose oprozomib . 25 . Patients must use potent CYP3A4 inhibitor ( i.e. , ketoconazole ) within 7 day prior enrollment , potent CYP3A4 inducer ( i.e. , rifampin ) within 14 day prior enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>